Systematic review of pathophysiological changes following hepatic resection  by Siu, Joey et al.
REVIEW ARTICLE
Systematic review of pathophysiological changes following
hepatic resection
Joey Siu1, John McCall2 & Saxon Connor1
1Department of Surgery, Christchurch Hospital, Christchurch, New Zealand and 2Department of Surgery, Dunedin Hospital, Dunedin, New Zealand
Abstract
Objectives: Major hepatic resection is now performed frequently and with relative safety, but is accom-
panied by significant pathophysiological changes. The aim of this review is to describe these changes
along with interventions that may help reduce the risk for adverse outcomes after major hepatic resection.
Methods: The MEDLINE, EMBASE and CENTRAL databases were searched for relevant literature
published from January 2000 to December 2011. Broad subject headings were ‘hepatectomy/’, ‘liver
function/’, ‘liver failure/’ and ‘physiology/’.
Results: Predictable changes in blood biochemistry and coagulation occur following major hepatic
resection and alterations from the expected path indicate a complicated course. Susceptibility to sepsis,
functional renal impairment, and altered energy metabolism are important sequelae of post-resection liver
failure.
Conclusions: The pathophysiology of post-resection liver failure is difficult to reverse and thus strat-
egies aimed at prevention are key to reducing morbidity and mortality after liver surgery.
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Introduction
Liver resection for primary and selected metastatic hepatic neo-
plasms can be performed safely with low rates of morbidity and
mortality.1 However, major liver resection is accompanied by sig-
nificant and to some extent predicable pathophysiological
changes. These range from mild transient abnormalities to pro-
gressive derangements that can be life-threatening in the case of
post-resection liver failure (PLF).2 Patients with pre-existent
parenchymal liver disease and/or a small residual liver volume
(RLV) are at greatest risk for PLF,1,2 the clinical features of which
are similar to those of liver failure in other contexts and include
coagulopathy, encephalopathy, jaundice and ascites. A compre-
hensive understanding of the pathophysiological changes that can
be expected after major hepatic resection is important to enable
surgeons to recognize deviations from the normal course at
an early stage. The aim of this review is to describe the
pathophysiological changes that occur following major hepatic
resection and interventions that may prevent or reduce the risk for
the development of those complications specifically associated
with hepatic resection.
Materials and methods
A literature search was performed using the MEDLINE, EMBASE
and CENTRAL (Cochrane Central Register of Controlled Trials)
databases for articles published from January 2000 to December
2011. The medical subgroup headings (MeSH) ‘hepatectomy/’,
‘liver function/’, ‘liver failure/’ and ‘physiology/’were used as broad
search terms. The search was performed according to PRISMA
(preferred reporting items for systematic reviews and meta-
analyses) recommendations (Fig. 1).To outline key components of
pathophysiological change after liver resection, the above MeSH
terms were combined using Boolean operators with the MeSH
terms ‘reperfusion injury/’, ‘liver ischaemia/’, ‘immunity/’, ‘liver
circulation/’,‘blood coagulation/’,‘blood cell count/’,‘metabolism/’,
‘liver function tests/’, ‘kidney function/’, ‘liver regeneration/’ and
‘liver hypertrophy/’. Additional articles were identified from the
references of articles highlightedby the electronic search.Eligibility
criteria required studies to have been published from January 2000
onwards, to refer to investigations in humans in which more than
eight patients underwent major hepatectomy, and allowed the
inclusion of randomized and non-randomized studies including
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observational studies without control groups, individual studies
and reviews with relevance to physiological topics. Exclusion cri-
teria discounted animal studies, studies in which only transplanta-
tion was performed, studies reported in languages other than
English and studies with insufficient data on physiological topics.
The selection of articles was conducted by two reviewers. Any data
obtained were confirmed by at least one other reviewer.
Results
Biochemical liver function tests
Commonly measured biochemical parameters of hepatic function
following liver resection include aspartate aminotransferase
(AST) and alanine aminotransferase (ALT), alkaline phosphatase
(ALP), γ-glutamyl transpeptidase (GGT), bilirubin, albumin and
C-reactive protein (CRP). Time-dependent change, influencing
factors and aetiologies of change are shown in Table 1.
Serum levels of bilirubin are dependent on the pre-hepatic load
of haem, hepatocellular function and rate of biliary excretion, all
of which can be altered in the postoperative period. A landmark
study by Balzan et al.,3 carried out in 2005, found that serum
bilirubin of >50 μmol/l combined with prothrombin time (PT) of
<50% of normal time (the so-called ‘50–50’ criteria) at day 5 was
associated with an odds ratio (OR) of 216 [95% confidence inter-
val (CI) 54–861] for predicting postoperative mortality with an
accuracy of 97.7%. The presence of either of these criteria alone at
any time after surgery was also associated with marked increases
in postoperative mortality.3
Albumin and CRP are synthesized by the liver and their post-
operative change has been studied in detail (Table 1). At day 1,
median albumin levels were found to be reduced from 42 g/l
[interquartile range (IQR): 38–46 g/l] and 44 g/l (IQR: 40–46 g/l)
to 26 g/l (IQR: 22–31 g/l) and 24 g/l (IQR: 21–26 g/l) in patients
submitted to minor and major hepatic resections, respectively.4 At
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Figure 1 Flow diagram showing the identification and screening of studies for review in line with PRISMA criteria
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day 7, median values of albumin appeared to remain significantly
lower than preoperative values at 32 g/l (IQR: 28–36 g/l) and
31 g/l (IQR: 28–33 g/l) in patients undergoing minor and major
hepatic resections, respectively.4 Acute changes in serum albumin
reflect the movement of albumin into the interstitial space in
response to tissue injury, rather than reduced liver synthesis, and
are exaggerated by systemic complications such as sepsis. The CRP
peaked at day 3 at 138 mg/l (IQR: 104–166 mg/l) and 86 mg/l
(IQR: 60–125 mg/l) in patients submitted to minor and major
hepatic resections, respectively.4
Levels of ALP and GGT rise during the first week after
major resection and remain elevated during the period of
liver regeneration. The increases in ALP and GGT may be exag-
gerated in pathological situations such as biliary obstruction
or small-for-size syndrome, in which intrahepatic cholestasis
occurs.5
Table 1 Changes to biochemical markers following hepatic resection
Test Peak or trough Influencing factors Marker of:
Transaminases
(AST/ALT)1,4,92
Peak at day 1 followed by exponential
decay
Time of surgery and hepatic ischaemia
Bilirubin level
Hepatocellular injury
Bilirubin2–4,93 Peak at day 3 (variable), biphasic
Falls at 3–12μmol/day
Early postoperative period:
Unconjugated/conjugated ratio: >1
Late postoperative period:
Unconjugated/conjugated ratio: <1
Day 1: preoperative bilirubin, duration
of surgery, blood transfused
Days 1–7: volume hepatic resection,
hepatic ischaemic time
>Day 7: sepsis
Preload of haem
Hepatocellular function
Rate of biliary excretion
Sepsis
C-reactive protein4,94 Peak at day 3 Rise is inversely proportional to extent
of resection (days 1–5)
Synthetic function
Hepatic failure following major hepatic
resection (<32 mg/l at day 1)
Complication (days 3–7)
Albumin4,94 Trough (>day 7) then slowly recovers Proportional to extent of resection
Presence of complication (days 1–5)
Synthetic function
Complication (days 1–7)
ALP, GGT93 Trough to approximately 7% of initial
value then slowly climbs at rate
14 U/l/day
GGT greater variability
Presence of biliary obstruction (can be
diagnosed by confirming elevated
cholesterol level)
Recovery correlates with normalization
of prothrombin activity
Regeneration
α-GST95 Peaks at 15–30 min after reperfusion Preconditioning can be protective Ischaemia
Postoperative hepatic dysfunction
(>490 μg/l at 2 h post-resection)
Glucose20,23,24,96 Rises within minutes of reperfusion;
elevation can persist for up to 16 h
Chronic liver disease or fibrosis
Hormonal manipulation (insulin,
cortisol, glucagon, noradrenaline)
Portal clamping
Glycogenolysis
Gluconeogenesis
Lactate20–22,92,93,97 Rises within minutes of reperfusion
and returns to normal within 24 h
Represents adequate capacity of
remnant
Degree of ischaemia (correlates with
AST rise)
Pre-existing liver disease
Ischaemia–reperfusion injury
Anaerobic hepatic metabolism
Systemic levels of lactate but not
intestinal lactate levels
Level >4–5 mmol/l associated with
hepatic failure (although time
course may be more important)
Serum creatinine45,46 Little change in immediate
postoperative period
Patients with a preoperative serum
creatinine of ≥ 155 mmol/l are less
predictable
Peaks at days 2–3
Raised preoperative serum creatinine
Impaired neurohumoral autoregulation
(diabetes, ischaemic heart disease,
hypertension)
Perioperative hypotension (low CVP)
Late sepsis/multi-organ failure,
post-resection liver failure
Acute kidney injury
Haemofiltration requirement
Phosphate/Ca2+16–19 Hypophosphataemia almost universal
(mean drop 47%)
Severe in up to 20% of patients
Nadir seen on days 2–3 and recovers
by day 7
Ca2+ reaches nadir 24 h earlier than
PO4−
Size of fall inversely proportional to
hepatic remnant volume and rise in
ALP
Inversely proportional to prothrombin
level
Increased urinary loss of phosphate:
mechanism unclear
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; GGT, γ-glutamyl transpeptidase;
α-GST, α-glutathione S-transferase.
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The administration of pre- and perioperative methyl pred-
nisone to patients undergoing hepatic resection has been shown to
reduce postoperative peaks in bilirubin and CRP levels, but no
differences have been noted in transaminase levels or the occur-
rence of complications.6
Coagulation changes after hepatic resection
The homeostasis of the coagulation system is closely related to
hepatic function because the liver is responsible for the synthesis
of factors involved in the coagulation and fibrinolytic pathways, as
well as regulation of their activators and inhibitors. The liver is
also, via the reticuloendothelial system, largely responsible for the
clearance of breakdown products of activated clotting factors.7
Thus, in patients with underlying cirrhosis, preoperative abnor-
malities in the clotting and fibrinolytic systems may coexist.7 The
platelet count is also reduced in portal hypertension. Patients with
prolonged obstructive jaundice may develop vitamin K deficiency
that results in alterations in both the clotting system via factors II,
VII, IX and X and the anticoagulant system via proteins C and S.7
Themagnitude of the changes to the coagulation profile have been
correlated with the extent of hepatic resection (weight of resected
specimen),8,9 amount of blood loss8 and time of surgery.9 In addi-
tion, the degree of change in the level of any individual factor will
be governed not only by impaired synthesis, but also by the rate of
consumption and half-life dependent decay.
Activated partial thromboplastin time (aPPT) and PT, or the
international normalized ratio (INR), are the most commonly
measured parameters of coagulation following hepatic surgery
(Table 2). In assessing the frequency at which these changes
(aPPT, INR) occur, it is important to take into consideration the
proportion of patients undergoingmajor hepatic resection,10,11 the
extent of blood loss11 and the amount of i.v. fluid administered11 in
association with the resection. In a series of 124 patients with
normal underlying hepatic function, in whom the mean ± stand-
ard deviation (SD) weight of the hepatic resection was
667 ± 443 g, PT was prolonged in 43% of patients at day 3 and in
22% at day 7,9 with a mean ± SD maximal value of 18 ± 3.8 s
(normal range: 11–16 s). It is also worth noting that some of the
immediate postoperative changes reflect the diluting effect of the
administration of i.v. fluid, whereas those at 24 h and later reflect
the amount of liver resected.11
Three studies8,9,11 have looked at the effect on platelets following
hepatic resection (Table 2). As expected, given that platelets
are not synthesized in the liver, the level of reduction was corre-
lated with the amount of blood loss and the amount of
intraoperative fluid administered, but not with the amount of
liver resected.11
Antithrombin III (AT-III) is a serine protease inhibitor that is
synthesized in the liver.10 It acts to neutralize thrombin and factor
Xa.10 Bezeaud et al. showed a fall to <50% of baseline, which
persisted to day 5 and coincided with similarly sized reductions in
levels of the coagulation inhibitor protein C.12 The same study12
measured levels of the prothrombotic marker thrombin-
antithrombin. The level of plasma thrombin–antithrombin com-
plexes indicate the degree of intravascular thrombin formation.12
In this study,12 despite the administration of prophylactic low
molecular weight heparin, a 10-fold increase in plasma levels of
thrombin–antithrombin complexes was observed from the
immediate postoperative period through to day 5. This has par-
ticular clinical significance: firstly, higher levels of thrombin–
antithrombin complexes within the first 48 h after surgery
were associated with an increased risk for subsequent thrombotic
complications, and, secondly, it questions what the most appro-
priate thrombotic prophylactic might be, given the acquired
antithrombin deficiency.12 Further evidence to support the devel-
opment of a procoagulant state following partial hepatic resection
has included the observation of increased factor VIII and von
Willebrand factor between days 1 and 5.12
Fibrinogen is an acute phase protein synthesized within the
liver. It is required for clot formation. Fibrinogen is expected to
increase following surgical trauma.13 After hepatic resection, this
increase has been found to be dampened proportional to the
magnitude of the hepatic resection.13 In addition, a temporal
failure to increase in the postoperative period is a predictor of
complications.13
Thus, it is clear that the balance between an anticoagulated and
thrombotic state is dependent on a complex interaction of multi-
ple factors. Standard clotting profiles would not seem to offer an
accurate or real-time assessment of the true underlying situation
or predict the likelihood of bleeding or complications. As more
detailed methods of making a real-time assessment of the clotting
pathways become commercially available, it may be appropriate
Table 2 Summary of changes in coagulation system following
hepatic resection
Factor Test Main findings
II, VII, IX, X8–11 INR/PT Immediate rise, peaks at days
1–3, normalizes at day 5
I, II, V, VIII, IX–XII8,10 aPPT Small immediate rise, peaks
(40–50 s) within 24 h and
normalizes within 48 h
Platelets8,9,11 Platelets Non-clinically significant fall with
nadir at day 3 returning to
normal at day 5
Antithrombin III10,12 AT-3 Extent of nadir proportional to
extent of hepatic resection
Level of <60% of baseline is
associated with procoagulant
state
Protein C12 Protein C Fall proportional to fall in AT-3
Protein S12 Protein S Transient fall returning to normal
within 24 h (extrahepatic
synthesis)
Fibrinogen13 Fibrinogen Dampened rise post-resection
proportional to magnitude of
resection
INR, international normalized ratio; PT, prothrombin time.
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to use these to tailor therapies to combat individually identified
deficiencies.
Clinical trials of thromboembolic prophylaxis specifically after
liver resection are lacking. However, patients undergoing major
abdominal surgery benefit from thromboembolic prophylaxis and
available evidence suggests that this is safe and effective in patients
undergoing liver resection,14 which is consistent with the known
effects of liver resection on both the pro- and anticoagulation
pathways.
Metabolic changes
Energy consumption by the liver following hepatic resection
increases to support protein synthesis for the acute phase response
to injury.15 However, hepatocyte mitosis during liver regeneration
incurs an additional burden in the maintenance of metabolic
function despite a decrease in liver mass.1,15 As a result of compet-
ing metabolic demands, an economic energy crisis occurs, with a
fall in energy state or ‘energy charge’, and some synthetic and
excretory functions are sacrificed.1 As energy production capacity
increases with successful regeneration, liver function recovers.15
Serum calcium and phosphate levels drop significantly in
the early postoperative period (Table 1).16–19 The routine treat-
ment of these remains controversial because although severe
hypophosphataemia can cause life-threatening complications, it is
not clear whether routine treatment reduces complications16,18 in
healthy patients. It would seem appropriate to institute phosphate
replacement should levels fall to <0.7 mg/dl.
Glucose homeostasis is maintained to a significant extent by
hepatic gluconeogenesis. The liver has a key role in the regulation
of plasma concentrations of lactate, a precursor of glucose,20 and
maintains up to 50% of the decomposition of lactate primarily via
gluconeogenesis.20 The liver can change from a lactate consumer
to a lactate producer by switching to anaerobic metabolism when
there is a reduced oxygen supply, such as during vascular clamping
in hepatic resection.20–22 Hyperglycaemia (Table 1) induced by
surgical stress is also recognized following liver resection.23 This,
in turn, impairs liver metabolism and immune function, thus
impacting on postoperative recovery.24
The liver plays an important role in amino acid metabolism,
protein synthesis and protein breakdown. It detoxifies end-
products of the intestinal metabolism, such as ammonia.
Hyperammonaemia is probably a causal component of hepatic
encephalopathy.25 An imbalance in plasma amino acids, which is
closely associated with hyperammonaemia,25 during liver failure
has also been implicated, and can be measured by the ratio
between branched-chain amino acids (BCAAs) and the aromatic
amino acids (AAAs), otherwise known as Fischer’s ratio.26
Fischer’s ratio is a useful indicator of the severity of hepatic paren-
chymal injury in patients with liver disease and severe hepatic
insufficiency.26 The pathophysiology of hyperammonaemia in
liver disease is complex. In 2008, van de Poll et al. reported that the
net splanchnic contribution of ammonia is only minor because
ammonia acid supply and metabolism per gram of liver increase
significantly immediately following hepatectomy.27 It has been
shown that hepatocellular ammonia clearance is also likely to be
preserved in the diseased liver.27 Therefore, even the diseased liver
has substantial reserve capacity. The kidneys also have a significant
role in the regulation of systemic ammonia release and thus thera-
pies aiming to reduce high ammonia levels may need to target
renal ammonia production and excretion in addition to intestinal
ammonia production.27
Amino acid imbalance with a reduced Fischer’s ratio in the
diseased or injured liver is caused by an increase in BCAA catabo-
lism in muscle and decreased AAA breakdown in the liver.25 A
reduction in the insulin/glucagon ratio may play a role in this
metabolic imbalance25 and may be reversed by supplemental
BCAA.28 In addition, the administration of BCAAs after major
hepatectomy has been shown to support protein synthesis and
regeneration of the remnant liver.26 Use of molecular adsorbent
recirculating systems (MARS) during liver failure suggests that a
low Fischer ratio can be corrected by recirculating albumin dialy-
sis; however, experience with MARS for PLF is limited and there is
no evidence to date that clinical outcome is altered.25,29
The effects of the Pringle manoeuvre on amino acid metabo-
lism alter individual amino acid levels, but the Fischer ratio
remains unchanged.25 In 2007, Dejong et al. found that in patients
who underwent hepatic resection without a Pringle manoeuvre
the Fischer ratio remained unchanged, but plasma AAA levels
were inversely correlated with RLV.25
Previous studies have shown a correlation of the ratio between
BCAAs and tyrosine (BTR) with liver function parameters such
as prothrombin and albumin in patients with liver disease.26
Increased BTR levels after hepatectomy were found to be associ-
ated with the prolonging of jaundice after liver surgery.26
Immune function
Rates of postoperative infection may reach 50% after major liver
resection30 and bacterial infection may develop in up to 80% of
patients with PLF in comparison with 20% of patients who do not
have PLF.30 Sepsis is the most common immediate cause of death
in patients with PLF. Several factors contribute to increased sus-
ceptibility to infection and the development of sepsis in patients
following liver resection. These include technical factors such as
wounds and collections of bile or blood, reduced capacity of the
reticuloendothelial system,31 and increased exposure to enteric
microorganisms, all of which occur in the setting of a surgical
stress response.32
Sepsis can also precipitate or exacerbate PLF as a result of the
inhibitory effect of sepsis on hepatic regeneration.1 Systemic
inflammatory response syndrome (SIRS) is likely to be implicated
in sepsis and end-organ dysfunction in PLF.32 This syndrome is an
index of surgical stress early after surgery and is predictive of
complications.33 Patients with sepsis can develop circulatory dys-
function as a result of haemodynamic instability and decreased
systemic vascular resistance.2,34 This may be further complicated
by the rapid development of multi-organ failure, such as in acute
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renal failure and acute respiratory dysfunction.2,34 The majority of
PLF patients will develop SIRS and multi-organ failure, and an
80%mortality rate has been documented in patients who undergo
resection of >50% of the liver.30,35
The reticuloendothelial system or Kupffer cell mass and func-
tion are reduced and show an S-shaped correlation to the extent of
resection.31 Kupffer cells play a significant role in the innate
immune system and produce cytokines [tumour necrosis factor-α
(TNF-α) and interleukin-6 (IL-6)], which induce proliferation of
hepatocytes.1 Thus the remnant liver is dependent on Kupffer cells
for regeneration as well as for the clearance of blood-borne enteric
microorganisms and endotoxins. Recovery of Kupffer cell func-
tion may not occur for >2 weeks after resection.1
The increased rate of bacterial translocation to the liver from
portal and arterial blood, mesenteric lymph nodes and other
organs may be attributed to reduced clearance and possibly to the
application of temporary hepatic inflow occlusion.1 Bacterial
endotoxins directly affect Kupffer cells by impairing the initiator
cytokines needed for regeneration.1 They also disrupt hepatocyte
transport mechanisms, membrane function and metabolism,
leading to hepatic necrosis.2
The liver responds to injury and infection by producing an
acute phase response in preparation for change in metabolic pro-
cesses, the removal of necrotic tissue, the mobilization of immune
cells and the reparative process.32,35 An excessive inflammatory
response with subsequent transient immunosuppression can lead
to increased susceptibility to infection, SIRS and consequent
multi-organ failure.35 Portal venous congestion associated with
hepatic inflow occlusion can upregulate the production of acute
inflammatory cytokines.36 A higher portal vein pressure correlates
with an increased inflammatory response and repeated intermit-
tent clamping has been proposed as a method to overcome this.36
Plasma IL-6, IL-10, IL-8, monocyte chemotactic protein-1
(MCP1), cortisol and leptin have been positively correlated with
infection and organ dysfunction following hepatic resection.32
Surgical stress causes an increase in energy requirements;
however, there is a decrease in hepatic energy levels in the first 48 h
after resection,37 which impairs liver regeneration. The ongoing
inflammatory activity in patients with chronic liver failure further
increases the risk for acute liver failure38 as a result of these
patients’ reduced ability to adapt to surgical stress.39
Several randomized controlled trials (RCTs) indicate that high-
dose steroid administration attenuates the surgical stress response
while reducing immune suppression in patients undergoing hepa-
tectomy.35,40,41 However, there is no evidence that this leads to an
improvement in clinically important endpoints.35,40,41
Strey et al. confirmed the role of complement activation in the
systemic inflammatory response whereby complement products
return to baseline by day 7.42 Early increases in C3a and soluble
terminal complex sC5b9 were found to be accompanied by an
early reduction in C4a and C5a.42 The same study found a decrease
in neutrophil chemotaxis and function, which suggests the
downregulation of neutrophil activity following hepatic resection.
However, only a reduction in C5L2 on monocytes was associated
with the impairment of postoperative liver function (bilirubin
and thromboplastin time) and no other postoperative clinical
data, such as incidence of complications, were given.42
Renal function
Two large series have shown postoperative acute kidney injury
(AKI) occurs in 15% of patients undergoing hepatic resection
(Table 1).43,44 Postoperative AKI is strongly associated with mor-
tality, which reaches 22.5% in patients with and 0.8% in those
without AKI (P < 0.001), as well as extended requirements for
intensive care unit (ICU) and hospital care.43 The four strongest
predictors43 of postoperative AKI are preoperatively elevated ALT,
pre-existing cardiovascular disease, chronic renal failure45,46 and
diabetes.43 Such patients have an impaired ability to autoregulate
glomerular blood flow during surgery and thus have an increased
risk for acute tubular necrosis.45
Increased blood loss during hepatic resection has been associ-
ated with greater risk for AKI.47 Low (<5 mmHg) intraoperative
central venous pressure (CVP) and fluid restriction are applied in
many centres to reduce blood loss.43,44,48 However, the use of low
CVP needs to be balanced against the risk for AKI.43,48 If mean
arterial blood pressure (MABP) falls to <80 mmHg, the
glomerular filtration rate (GFR) drops significantly, leading to an
increased risk for the development of AKI.43,44 Postoperative renal
function may be impaired by a low arterial blood pressure43
arising from the hypovolaemic state caused by low CVP anaesthe-
sia and portal inflow occlusion. A low perfusion state can also
occur secondary to cardiac dysfunction or distributive circulatory
changes, such as sepsis or hepatorenal failure.45 Patients who
develop PLF show haemodynamic changes similar to those in
patients with cirrhosis or acute liver failure of other causes and are
at risk for hepatorenal syndrome, particularly when bacterial
sepsis ensues.43,44 Cardiac output is increased and blood flow is
redistributed towards the splanchnic circulation and away from
the systemic vascular bed in response to increased levels of nitric
oxide (NO).43,44 These changes lead to reduced central and arterial
blood volume, low pulmonary capillary wedge pressure, low CVP,
low systemic vascular resistance, increased carbon monoxide, and
reduced MABP.43,44 Hepatorenal syndrome results from reduced
renal blood flow and activation of homeostatic mechanisms that
produce renal arteriolar vasoconstriction.43,44 Perioperative man-
agement to prevent mortality from hepatorenal syndrome
includes optimizing the patient’s fluid status,43 and remaining
vigilant for and providing early management of sepsis.30
Terlipressin is a vasopressin analogue that redistributes blood flow
from the splanchnic to the renal circulation.49 In the setting of
chronic liver disease, terlipressin, alone or with albumin, reduces
the mortality associated with hepatorenal syndrome.49 The role of
terlipressin in PLF has not been tested, but it is reasonable to
consider that it may be beneficial in patients who develop
hepatorenal failure in this context.
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Hepatic blood flow
Hepatic blood flow is complex and regulated at three levels in
normal physiological situations: the systemic circulation; the
regional (macro) circulation, and the micro circulation.50 Factors
controlling each of these levels and the effects of interventions are
shown in Table 3.
Ischaemia and reperfusion
Ischaemia–reperfusion injury (IRI) occurs following liver resec-
tion with hepatic inflow occlusion. The severity of hepatic IRI
correlates with the time of ischaemia and clinical factors, such as
the duration of the procedure, periods of intraoperative hypoten-
sion and the degree of splanchnic ischaemia, most of which are
under the surgeon’s control.51 In addition to ischaemic injury to
the liver, hepatic portal triad clamping causes intestinal venous
congestion.36,51 Stagnant portal venous blood stimulates inflam-
matory mediators that exacerbate IRI to the liver.36 The reflow of
stagnant portal venous blood into the ischaemic liver is detrimen-
tal to hepatic energy metabolism and therefore subsequently
affects the liver’s ability to maintain function and regenerate.51
Diseased hepatic parenchyma is more susceptible to IRI51–53 and
should not be exposed to >60 min of continuous warm ischae-
mia,40 although periods of up to 90 min have been shown to be
well tolerated by normal liver.51,54 A recent systematic review
found that intermittent portal triad occlusion provides better pro-
tection against IRI in patients with chronic liver disease than does
continuous portal triad occlusion.55
There are three main components of IRI.56 The first concerns
cellular activation; the second refers to the expression of adhesion
molecules (Fig. 2), and the third to microcirculatory dysfunction.
These are linked by various mediators including cytokines,
chemokines, lipid mediators and complement factors. The
mechanisms of IRI leading to cellular injury are summarized
in Fig. 3.
In two RCTs involving, respectively, 66 and 60 patients and
evaluating the effects of a synthetic protease inhibitor, gabexate
mesilate, postoperative serum transminases were markedly
reduced, IL-6 production was suppressed and rates of postopera-
tive complications were lowered.57,58
Ischaemic preconditioning is a process by which the liver devel-
ops increased protection against IRI through the release of adeno-
Table 3 Factors controlling and interventions affecting hepatic blood flow (HBF)
Level Flow Regulation Effect of intervention
Systemic50,98,99 Total HBF ↓ in HBF seen with:
Ë ↓ CO
Ë ↓ SVR (other than splanchnic)
Ë ↑ RAP > PVP
Inflow occlusion results in:
Ë MAP and ↓ CVP
Ë ↓ Blood loss
Hepatic venous exclusion:
Ë Well tolerated
Ë ↓ CVP and CO
Ë MAP maintained >55 mmHg as a result of ↑ in SVR
Infrahepatic caval clamping:
Ë Well tolerated
Ë ↓ Blood loss
Regional50,66,100,101 Total HBF Total HBF (constant) = HAF + PVF (hepatic arterial
buffer response)
Inflow occlusion followed by reperfusion results in
Ë ↓ SVR:
Ë Total HBF constant
When preconditioning used:
Ë Total HBF
Laparoscopic surgery:
Ë No difference in effect of inflow occlusion using
laparoscopic or open surgery
PVF Passively drains splanchnic arterial bed so ↓
splanchnic flow results in ↓ PVF
Inflow occlusion followed by reperfusion results in:
Ë 29% ↓ in PVF on reperfusion lasting >30 min
When preconditioning used:
Ë No change in PVF
HAF No auto-regulatory activity
↓ HAF with ↑ arterial resistance
Arterial resistance ↑ with ↑ PVF (hepatic arterial
buffer response)
Inflow occlusion followed by reperfusion results in:
Ë 8% ↑ in HAF on reperfusion lasting >30 min
When preconditioning used:
Ë 200% ↑ in HAF
Micro50,66 HSF Flow controlled by diameter of the sinusoids
Sinusoidal diameter controlled by sinusoidal
endothelial cells, hepatic stellate cells and Kupffer
cells
Mediators released by above cells alter degree of
contraction or relaxation of the cells, thus altering
sinusoidal diameter and hence resistance to flow
Ischaemia and subsequent reperfusion create a
mismatch in time and space of mediator release
so that homeostasis of the mediators is lost
CO, cardiac output; CVP, central venous pressure; HAF, hepatic artery flow; HSF, hepatic sinusoidal flow; MAP, mean arterial pressure; PVF, portal
blood flow; PVP, portal blood pressure; RAP, right atrial pressure; SVR, systemic vascular resistance.
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sine, decreased endothelin-1 (ET-1) expression, altered nitric
oxide synthase (NOS) induction, suppressed cytokine and free
radical release, and transcriptional activation of stress genes, such
as heat shock proteins, and adenosine triphosphate (ATP)
preservation.59–63 An increase in carbon monoxide is protective
because it helps to maintain microvascular and portal blood flow
by regulating NOS and vasodilation.61 Studies show that the
ultrastructure of parenchymal and non-parenchymal cells can be
maintained even when the accumulated ischaemic duration with
intermittent portal clamping is extended to 120 min.64
Efforts to improve hepatic tolerance of IRI have included the
use of high-concentration glucose administered i.v. 24 h prior
to surgery with the aim of increasing hepatocellular glycogen and
ATP content.65 Heizmann et al. found that improved hepatic
macrocirculation (Table 3) in addition to hepatic microcircula-
tion following ischaemic preconditioning offered protection
against IRI.66 A systematic review of RCTs discussing pharma-
logical interventions that aim to ameliorate IRI, many of which
were small, individual, clinical studies, shows that none so far
demonstrate any clinical benefit.67 Ischaemic preconditioningmay
be achieved surgically by exposing the liver to a brief period (often
10 min) of ischaemia followed by 10 min of reperfusion prior to a
prolonged ischaemic period.63 It is thought that the first period of
portal clamping in the intermittent portal clamping method pro-
vides similar effects through a form of ischaemic precondition-
ing.62 Ischaemic preconditioning also appears to have a protective
effect when the selective hepatic vascular exclusion (SHVE)
manoeuvre (with inflow and outflow occlusion) is applied.68
However, the effects of ischaemic preconditioning under hepatic
inflow occlusion in normal liver were not found to translate into
significant reductions in mortality, liver failure, perioperative
morbidity, hospital stay and ICU stay in a systematic review of five
trials.69 In addition, a systematic review of four RCTs comparing
hemihepatic with total hepatic inflow occlusion reported no sig-
nificant difference in the clinical outcomes of blood loss, transfu-
sion requirement, mortality, morbidity, operating time and
hospital stay.70 In patients with livers at increased risk for the
effects of ischaemia and reperfusion (cirrhotic, fibrotic or steatotic
Figure 2 Role of adhesion molecules in ischaemia–reperfusion injury. ICAM-1, intercellular adhesion molecule-1; MAC-1, macrophage-1
antigen; MCP1, monocyte chemotactic protein-1; ROS, reactive oxygen species; TNF-α, tumour necrosis factor-α; VCAM-1, vascular cell
adhesion molecule-1; XDH, xanthine dehydrogenase; XOD, xanthine oxidase. References: 56,89–91
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livers), the potential of the hemihepatic inflow occlusion
approach remains to be explored.70,71
Liver regeneration
Liver regeneration is particularly significant in the context of
major hepatic resections and small-for-size syndrome.72 The
elevation in portal pressure that results from extended liver resec-
tion causes excess shear stress on the remnant liver with a reduc-
tion in portal vein flow and ultimately impaired regeneration.1,73
Much of the current understanding of physiological pathways in
liver regeneration stems from extensive research in animal
models.72,74 There are few data on the precise timing of the pro-
cesses involved in humans.72 By contrast, the volumetric and func-
tional recovery of the liver has been studied more extensively in
patients following donor hepatectomy. In a series of 27 donors
who underwent right hepatectomy, the remnant liver increased to
74% of its original volume at postoperative day 10 and continued
to reach 83% of its original volume at 12 months.75
The liver will regenerate in response to loss of liver mass or liver
function in order to restore functional liver volume.72,76 A larger
resection or greater tissue damage will result in an increased rep-
lication rate.76 Proliferation of all liver cell types occurs, but non-
parenchymal cells (endothelial, Kupffer and biliary duct cells) will
have a more delayed course.74 Cells undergo cell cycle reactions
(G1–G1) until a liver mass matched to body size is restored.72
Signalling pathways lead to an important G1–S transition in
which liver cells commit to division and the time from G0 to
S phase will depend on cell type.72 The role of the ‘oval cell
compartment’ originating from ductular cells in generating
hepatocytes and bile duct cells post-hepatectomy has not been
established as it has in toxic liver injury and other forms of liver
damage.72 Bone marrow-derived cells appear to contribute to
further cellular resources capable of restoring liver mass.77
Endothelin–
nitric oxide 
imbalance
α
IL-1 
Figure 3 Summary of mechanisms in ischaemia–reperfusion injury. IL-1, interleukin-1; ROS, reactive oxygen species; TNF-α, tumour
necrosis factor-α. References: 56,89
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Factors triggering or influencing hepatic regeneration are
shown in Table 4. Insulin and other growth factors that facilitate
hepatic regeneration are delivered via portal blood to the liver.
Other factors, such as glucagons, transforming growth factor-β
(TGF-β) and glucocorticoids will inhibit regeneration.72 Signals of
the cascade leading to proliferation are integrated to allow regen-
eration to occur in a synchronized fashion.74 The signal for cells to
return to G0 (quiescent phase) is unknown and may be related to
TGF-β or activin, potent inhibitors of hepatocyte growth.72
Impaired biliary drainage or biliary obstruction impedes liver
hypertrophy and regeneration78,79 (Table 4). Portal hyper-
perfusion and/or impaired venous outflow have been implicated
in the failure of normal regeneration to occur in small-for-size
syndrome.5
The increase in liver volume is an indicator of regeneration;
computed tomography (CT) is an easy, non-invasive imaging
modality for measuring liver volume.79 However, volume restora-
tion may be overestimated in CT as a result of postoperative
vascular engorgement or oedema.79,80 Nagino et al. found a poor
correlation between regeneration measured by CT volumetry and
postoperative liver dysfunction.79 Liver volumemay not accurately
reflect the quantity of hepatocytes, especially in cirrhotic livers.80
Galactosyl-human serum albumin scintigraphy (GSA) is a
method of estimating functional liver mass and was compared
with CT liver volume in 32 patients undergoing liver resection.80
Whereas volumetric regeneration reached 90% at 1 month,75,80 6
months were required for functional regeneration to reach the
same level.80 Surprisingly, functional gain in the diseased liver
(chronic hepatitis or cirrhosis) was more rapid and more com-
plete than volumetric recovery.80
Postoperative changes in phosphoester biochemistry or energy
metabolism as detected by proton-decoupled 31P magnetic reso-
nance spectroscopic imaging relate to the rate of liver regenera-
tion.81,82 The derangement in phosphoester metabolism is
increased in cirrhotic liver following resection.82 Zakian et al.
showed that following the time course of the recovery of
phosphoester metabolism may aid in making a clinical judgement
of the appropriate timing for adjuvant chemotherapy.81
Pharmacological approaches to improve liver regeneration have
so far mostly been investigated in animal studies.74,83 In a double-
blind RCT, pentoxifylline was found to improve the regeneration
of small remnant livers (ratio of remnant liver to body weight:
≤ 1.2%) based on three-dimensional volumetry by magnetic reso-
nance tomography at postoperative day 8. This effect was believed
to have been mediated by IL-6.83 However, morbidity and mortal-
ity outcomes did not differ significantly from those in the control
Table 4 Factors affecting regeneration following hepatic resection
Factors Effect
Hepatic arterial buffer
response
Same total portal flow through smaller hepatic volume carries hepatotrophic factors72,78
Hepatocyte injury Increase in circulating cytokines, IL-6, TNF-α stimulates priming factors for cell cycle activation72,78
Increased energy requirement triggers release of hepatocyte growth factor, TGF-α and epidermal growth factor72,78
Ischaemic
preconditioning
There are few clinical data on the beneficial effects of ischaemia preconditioning on liver regeneration compared with
IRI;102 however, it has been shown to protect against IRI, which impairs liver regeneration following hepatectomy
Biliary obstruction Reduces hypertrophy rate and regeneration following PVE or hepatectomy through a restricted portal venous flow
caused by hepatic fibrosis, altered signalling pathways associated with regeneration, and an impaired enterohepatic
circulation78
Patients with obstructive jaundice treated by external biliary drainage prior to hepatic resection may have impaired liver
regeneration as a result of the disruption of the enterohepatic circulation79
Diabetes Patients with diabetes have reduced synthesis of RNA, DNA and protein on day 1 post-hepatectomy, as well as
reduced hypertrophy caused by lack of insulin, a hepatotrophic factor78
Nutrition Patients with malnutrition have decreased regeneration following hepatectomy and higher postoperative mortality as
regeneration capacity depends largely on availability of energy37,78,82
Enteral feeding will help to produce a better portal venous flow favouring regeneration78
NASH has not been shown to affect liver regeneration, which shows over-nutrition probably has a small effect on
regeneration capacity78,103
Cirrhosis Recovery of lost cell mass is delayed and achieved incompletely, which is consistent with a higher risk for liver failure
and mortality in the early postoperative period82
A postoperative fall in hepatic ATP energy state is more sustained in cirrhotic liver82
The normal liver will modulate energy metabolism or ‘hepatic energy economy’ in order to accommodate an increased
metabolic load, but nonetheless develops a declined energy state around postoperative day 4, at the time when the
liver reaches its maximal regenerative capacity, while curtailing its normal differentiated functions81,82
This recovery process is delayed in cirrhotic liver and is probably related to its decreased flexibility in making economic
adjustments post-hepatectomy82
Gender The female gender may be more favourable towards regeneration as a result of the differential effects between the
genders of sex hormones on regeneration78
ATP, adenosine triphosphate; IL-6, interleukin-6; IRI, ischaemia–reperfusion injury; NASH, non-alcoholic steatohepatitis; PVE, portal vein embolization;
TGF-α, transforming growth factor-α; TNF-α, tumour necrosis factor-α.
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Table 5 Clinical recommendations and areas of future potential research in patients undergoing hepatic resection
Purpose Clinical recommendation Potential areas of research
Preoperative identification
of patients at high risk
for complications
Assessment and optimization of both function and
volume of FLR
Standard definition of risk of FLR based on volume
and functional status
Development of predictive nomograms
Prevention of complications
Intraoperative techniques
Optimization of comorbidity including cardiac, renal (Cr
> 155 mmol/l) and metabolic43,45,46
In patients undergoing preoperative biliary drainage
ensure bile is returned via enteric tract78,79
Cessation of hepatoxic agents (e.g. alcohol,
chemotherapy) and period of recovery prior to surgery
Role of reversal of hepatic steatosis prior to hepatic
resection
In high-risk patients consider use of perioperative
methyl prednisone6,35,40,41
Large multicentre RCT of steroids with well-defined
group of patients at high risk for postoperative
complications to determine if improvements occur
in clinically significant endpoints
Preoperative manipulation of the FLR in high-risk
subgroups78,85,86
RCTs may not be ethically viable; using predictive
nomograms and measuring variance may be a
better solution
In patients at high risk for small-for-size syndrome or
impaired regeneration, consider use of 5 days of
BCAA and human growth factor84
Determine role of manipulation of splanchnic blood
flow either surgically or pharmacologically
Avoid unnecessary invasive foreign bodies such as
catheters, drains and i.v. lines
In patients at risk for AKI, ensure MAP remains at
>80 mmHg43,44
In patients in whom IRI is likely to result in an adverse
outcome, adopt the following strategy:40,51,54
Intermittent inflow occlusion
Hemi-inflow occlusion70,71
Use of gabexate mesilate57,58
Period of ischaemic preconditioning59–63
Determine the efficacy of terlipressin in those with
hepatorenal syndrome post-hepatic resection
Optimization of coagulation
status
In patients undergoing extensive liver resection (>50%)
consider:
Real-time assessment and correction of coagulation
deficits12
Further real-time physiological studies on changes to
coagulation system as a whole and effect of
correcting deficits on clinical outcomes
Treatment with AT-3 if coagulation falls to <60% of
baseline level12
Identification of optimal treatment to correct deficits
(e.g. factor-specific or generic)
Use of DVT prophylaxis as per international guidelines14 Identification of patients who benefit from prolonged
DVT prophylaxis
Early postoperative
identification of
patients at risk for
complications
In high-risk patients:
Early assessment of predictors of PLF: (CRP < 32 mg/l
at day 1, α-GST at >490 μg /l at 2 h postoperatively,
lactate >4 mmol/l)
Monitoring for AKI
Early identification of sepsis:
↑ Bilirubin >day 7
↑ CRP at day 3
Further clinical assessment to determine optimal
variable and cut-off to determine optimal positive
and negative predictive values
Treatment of complications Aggressive management of suspected sepsis as per
international guidelines2,30
Treatment of hypophosphataemia if <0.7 mmol/dl16,18 Determine if treatment of PO4− improves clinical
outcome
Tight glucose control in perioperative period24 Determine optimal method of lowering serum
ammonia
Supplement nutrition with BCAA26 Determine if MARS has any clinical benefit in
patients with PLF
AKI, acute kidney injury; AT-3, antithrombin-3; BCAA, branched-chain amino acids; CRP, C-reactive protein; DVT, deep venous thrombosis; FLR,
future liver remnant; α-GST, α-glutathione S-transferase; IRI, ischaemic–reperfusion injury; MAP, mean arterial blood pressure; MARS, molecular
adsorbents recirculation system; PLF, postoperative liver failure; RCT, randomized controlled trial.
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group.83 Luo et al. studied the effects of the provision of BCAA
and recombinant human growth factor for 5 days on the remnant
liver in 24 hepatocellular carcinoma (HCC) patients with liver
cirrhosis and found improved recovery of liver function, protein
synthesis and regeneration.84
Portal vein embolization (PVE) and two-stage hepatectomy
represent two strategies which have been used in clinical practice
to increase the volume of the future liver remnant (FLR) and
reduce the risk for postoperative liver insufficiency. The reduc-
tions in postoperative mortality and morbidity following PVE in
both healthy and diseased liver have been documented in many
observational studies, although most of these were retrospec-
tive.78,85,86 Portal vein embolization is usually considered when the
FLR is estimated to be <25–35% of the whole liver in patients
with a normal liver and <40% in patients with underlying paren-
chymal disease and patients who are undergoing preoperative
chemotherapy.86 The haemodynamic changes that occur after
PVE are not as dramatic as those following partial hepatectomy
and therefore activation of liver proliferation occurs less
rapidly.78 Despite this difference, hepatic regeneration occurs via
similar mechanisms.78
After PVE, hepatic arterial flow to the embolized and non-
embolized lobes increases via the ‘hepatic arterial buffer
response’.1,78 Portal venous flow is diverted to the non-embolized
lobe to maintain drainage from the splanchnic circulation.1,78 The
non-embolized lobe thus receives a total increase in blood supply,
which results in hypertrophy, while the embolized lobe atrophies
in response to its reduction in total blood supply.78 The differen-
tiated function of the embolized lobe is likely to be maintained.78
Failure of the non-embolized lobe to regenerate after contralateral
PVE is considered by some to be a risk factor for poor function of
the FLR and a relative contraindication to proceeding with resec-
tion.87 Dual embolization (PVE followed by arterial embolization)
has been proposed as a method to further increase blood flow to
the non-embolized lobe and thus to improve the hypertrophy
rate.78 A retrospective study comparing two-stage hepatectomy
and PVE with one-stage hepatectomy in 43 hepatectomy patients
with multiple bilobar colorectal metastases showed that the FLR
hypertrophy ratio relative to pre-procedure volume in the two-
stage group (50.2%) was twice that in the PVE group (25.3%).88
However, the difference in longterm survival is unknown and a
multi-institution prospective study of two-stage hepatectomy is
yet to be carried out.
Discussion
Limitations
Because of the breadth of the current review, the range of study
types and the essentially descriptive nature of much of the infor-
mation reviewed, no assessment of bias or the grade quality of
individual studies was performed in this review. In addition,
because of the lack of high-level evidence, no objective grading
was performed for any specific intervention; however, Table 5
provides a narrative description of potential interventions and
considers areas for further research. The literature search was
limited to English-language studies within the search period and
included less recent papers that remain highly relevant. Because of
the wide range of subtopics, it is possible that some relevant
literature may not have been identified by the electronic search
strategy. Therefore, any landmark studies or other relevant studies
identified through hand-searching were considered for their eli-
gibility for inclusion.
Conclusions
Patients undergoing liver resection incur pathophysiological con-
sequences which relate to hepatocellular injury and reduced
hepatic mass. Most patients undergo rapid regeneration, but in
some the residual mass is either insufficient or regeneration is
disordered and these patients are at risk for PLF and other asso-
ciated complications. These changes are influenced by preopera-
tive factors including liver parenchymal disease, patient age and
comorbidities, intraoperative factors including the extent of resec-
tion, blood loss and ischaemia, and postoperative factors such as
sepsis and other systemic complications. The recognition of any
deviation from the expected path to recovery is important because
although there is limited high-level evidence for specific treatment
modalities for PLF, patients require careful and vigilant supportive
care through a prolonged recovery phase. Most interventions
tested to date have not been found to have conclusive effects on
morbidity and mortality. However, further research and attention
to clinical factors and their pathophysiological effects following
liver resection may help to improve patient selection, inform the
choice of procedure, and recognize and deal with complications at
an early stage.
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